Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
about
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceMetronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma modelTranscriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsMetronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memoryMetronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma modelNext generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Heparanase is required for activation and function of macrophages.Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells
P2860
Q27023579-5977D223-91B5-4E64-B4E1-1888DDDDBBA7Q34173568-3375A510-261F-4B66-B4EA-451061CCD428Q35624661-DA1CA4A4-3DD9-4B9C-BB56-8DEB2F754759Q35799297-06EFD9EC-EFF0-42B2-820C-59DF159FE1F3Q36101917-E52F5CBD-FDA8-4762-9117-8ABE79FF67DEQ36600960-CB5AFF2E-B486-4FCD-B551-2324A28010C1Q37458763-B23A7765-FEC1-4D4F-BFEF-1A5873072964Q37473740-A18E337F-E1F6-4B8D-86AA-5212E838FBA7Q38789551-4559FFE3-E6E8-4C81-B97B-FBD4751D3C2FQ48508291-86BC4750-136E-43FD-9280-DA13C6BDCD11Q55346913-F5D1C445-0685-41AB-A1D2-719C52FDE927
P2860
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@en
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@nl
type
label
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@en
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@nl
prefLabel
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@en
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@nl
P2860
P356
P1433
P1476
Anti-tumor innate immunity act ...... ugs that spare VEGF receptor 2
@en
P2093
Chong-Sheng Chen
P2860
P2888
P356
10.1186/1476-4598-13-158
P577
2014-06-26T00:00:00Z
P5875
P6179
1026276258